Company Overview
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Why Investors Should Care
Trades at a P/E of 19.2, below the sector median of 24.8.
Offers a dividend yield of 4.10%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $17.83B (-1.0% YoY); net profit $895.00M.
- Trailing 12 Months Year-on-year growth — revenue +0.5%, earnings +61.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.01% |
| 1 Year: | 0.50% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 61.40% |
Stock Price Performance
| 1 Year: | -3.72% |
| 6 Months: | -10.69% |
| 3 Months: | -2.05% |
| 1 Month: | -5.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.44 · Neutral
P/E of 19.16 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 4.10%.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PHG Koninklijke Philips N.V. PHARMA | 25.29 | 19.16 | $24.72B | 4.10% | 7.46% | 10.15% | 0.01% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 4.34B | 4.30B | 5.10B | 3.90B | 4.36B |
| Cost of Revenue | 2.33B | 2.39B | 2.81B | 2.14B | 2.21B |
| Gross Profit | 2.01B | 1.91B | 2.29B | 1.77B | 2.15B |
| Operating Expenses | 1.61B | 1.58B | 1.72B | 1.52B | 1.54B |
| Operating Income | 401.00M | 330.00M | 565.00M | 242.00M | 610.00M |
| EBITDA | 683.00M | 656.00M | 800.00M | 538.00M | 1.02B |
| Interest Expense | 80.00M | 78.00M | 56.00M | 83.00M | 95.00M |
| Pretax Income | 337.00M | 275.00M | 466.00M | 190.00M | 546.00M |
| Tax Provision | 95.00M | 87.00M | 74.00M | 44.00M | 160.00M |
| Net Income | 240.00M | 184.00M | 395.00M | 151.00M | 384.00M |
| Diluted EPS | 0.25 | 0.19 | 0.42 | 0.16 | 0.40 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 17.83B | 18.17B | 18.02B | 17.83B |
| Cost of Revenue | 10.63B | 10.72B | 10.25B | 9.78B |
| Gross Profit | 7.19B | 7.45B | 7.77B | 8.06B |
| Operating Expenses | 7.37B | 7.62B | 7.26B | 6.61B |
| Operating Income | -177.00M | -168.00M | 513.00M | 1.45B |
| EBITDA | 115.00M | 1.04B | 1.85B | 2.60B |
| Interest Expense | 244.00M | 306.00M | 337.00M | 294.00M |
| Pretax Income | -1.73B | -526.00M | 123.00M | 1.18B |
| Tax Provision | -113.00M | -73.00M | 963.00M | 282.00M |
| Net Income | -1.61B | -466.00M | -702.00M | 895.00M |
| Diluted EPS | -1.68 | -0.49 | -0.75 | 0.94 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 30.69B | 29.41B | 28.98B | 26.94B |
| Current Assets | - | 10.26B | 9.94B | 10.02B | 9.93B |
| Cash & Equivalents | - | 1.17B | 1.87B | 2.40B | 2.79B |
| Inventory | - | 4.05B | 3.49B | 3.20B | 2.87B |
| Receivables | - | 3.83B | 3.73B | 3.51B | 3.34B |
| Total Liabilities | - | 17.41B | 17.34B | 16.93B | 15.96B |
| Current Liabilities | - | 7.93B | 8.29B | 8.14B | 7.51B |
| Long Term Debt | - | 6.17B | 6.09B | 6.19B | 6.05B |
| Total Debt | - | 7.34B | 7.61B | 7.49B | 7.81B |
| Total Equity | - | 13.25B | 12.03B | 12.01B | 10.96B |
| Shares Outstanding | - | 952.31M | 944.73M | 939.94M | 962.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -173.00M | 2.14B | 1.57B | 1.17B |
| Investing Cash Flow | - | -1.49B | -636.00M | -573.00M | -737.00M |
| Financing Cash Flow | - | 500.00M | -848.00M | -496.00M | 107.00M |
| Capital Expenditure | - | -806.00M | -644.00M | -676.00M | -668.00M |
| Free Cash Flow | - | -979.00M | 1.49B | 893.00M | 504.00M |
| Net Change in Cash | - | -1.17B | 776.00M | 487.00M | 532.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 40.4% | 41.0% | 43.1% | 45.2% |
| Operating Margin % | -1.0% | -0.9% | 2.8% | 8.1% |
| Net Margin % | -9.0% | -2.6% | -3.9% | 5.0% |
| ROE % | -12.1% | -3.9% | -5.8% | 8.2% |
| ROCE % | -0.8% | -0.8% | 2.5% | 7.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Exor N.V. | 18.92% | 185.93M | $4.59B |
| 2 | Mondrian Investment Partners Ltd | 0.82% | 8.07M | $199.11M |
| 3 | Dimensional Fund Advisors LP | 0.44% | 4.34M | $107.13M |
| 4 | Fiduciary Management, Inc. | 0.35% | 3.46M | $85.39M |
| 5 | Causeway Capital Management LLC | 0.31% | 3.06M | $75.57M |
| 6 | Morgan Stanley | 0.30% | 2.94M | $72.45M |
| 7 | FMR, LLC | 0.27% | 2.65M | $65.50M |
| 8 | Brandes Investment Partners L.P. | 0.22% | 2.21M | $54.55M |
| 9 | Northern Trust Corporation | 0.21% | 2.09M | $51.47M |
| 10 | Blackrock Inc. | 0.20% | 2.00M | $49.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHG
Philips' $699.95 hair-removal device talks you through treatment - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQSTFOSXY3N0s4MDZubEJrWXEzcldqQXRySmtvMzR4QmE1RDBCcGdpN3FFUkFBT0tUeGVQNW1iLVZ5QW5sN29zNFJRNUJrUkRwTlZRS01sN3ZCNHV4U3I2UzI3TGNvaVJMQS1LSklSR285VDNLbXVsTkcteHY3dDZTUjYyNGVHTzFpWDVaOW…
Philips announces exchange ratio for 2025 dividend - Philips
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNVEtnUHphM3pma2R3SW9ZN2Jfb2wwQWtxZGdhNDVYZmdFZjI0WDRtVjJIZUQ1UGdWcGlvUzFBaUFIaV95YkR1ZWZ1clVkblR3d0NtMXhGU0JWeWZleml2WEFoRm5IQmZfUm1OV3pVOTU3cHF4bjZCYTAxWHV3UUFWMVcyWjhnV2NyeGR5aU…
Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPS05jMW9Wcy1mT1dLeUJPWEl1NHl2R2pvR0NQVU9zLXF0WlJRWldsREFWSTkzeVhyR2VvNWgzcWZPZU1VVHFZekdYbGNZZFlfNG9nOVpPWHVHRjJqQWwxTEtGZGhmSVdWWkhWallpRGIwRVc3TXpRWEUzTnRhVW85Nnd5Q3ljczQxWFRnMG…
Philips Stock Sinks To 52-Week Low - Here's Why - Koninklijke Philips (NYSE:PHG) - Benzinga
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxObXlOOUJ1ejFEaDRBN2xVQXRLbkpURTZuQnJqZXBKTXktVXJidi1TMlQ2a3RxOEJhMFM0M092a2JUalVmTVRFU1Z3NmdBU042WE10ZzNsczJ2NFFmUjFfZTZ5SzgxM1ZBdjBVTUM1VnFlSGo0M2QzUExXelBxRGxzLVZQUWJ2OGszY213Rj…
PHG - Koninklijke Philips NV ADR Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE5CbjRoTUhPM1lDMmNMb0ZVcW1CbmFIbG1uNzhyTllQNk8wMHZMUFAwSWdGNmxWZmpUY2RfNlQtOUdRSHY2?oc=5" target="_blank">PHG - Koninklijke Philips NV ADR Stock Price and Quote</a> <font…
How (PHG) Movements Inform Risk Allocation Models - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPRlJDYUtEblNtNVhHTml6RUI5MHp1VnliZlRvNk1wWm5WVmFOMW5OaGZjQ19RcndONV9YTm9uV1ZSUnJnZVJlWDM0RmJidm92Tl9RQnRTaFB6Q1Zsa3Rvcy1KYlkxalhzVG9ONHFsQVZWWXVLbXhrYUlJRjRYQW5FME9LUG1sMmtYZkFtMk…
PHG — Frequently Asked Questions
What is the current share price of Koninklijke Philips N.V. (PHG)?
As of 2026-09-19 21:16 PDT, Koninklijke Philips N.V. (PHG) trades at $25.29 on NYSE. Its 52-week range is $24.62 to $31.68.
What is the market capitalisation of PHG?
Koninklijke Philips N.V. (PHG) has a market capitalisation of $24.72B on NYSE.
What is the P/E ratio of PHG?
PHG trades at a trailing price-to-earnings (P/E) ratio of 19.16. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.81.
Does PHG pay a dividend?
Koninklijke Philips N.V. (PHG) currently offers a dividend yield of 4.10%.
What is the return on equity (ROE) of PHG?
PHG has a return on equity (ROE) of 10.15%. Its return on capital employed (ROCE) is 7.46%.
Is PHG a good stock to buy?
This page provides a data-driven analysis of Koninklijke Philips N.V. (PHG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.